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Increased	  Levels	  of	  IgG	  An2bodies	  against	  Human	  	  
HSP60	  in	  Pa2ents	  with	  Spondyloarthri2s	  
I	  n	  t	  r	  o	  d	  u	  c	  t	  i	  o	  n	   C	  o	  n	  c	  l	  u	  s	  i	  o	  n	  s	  
①  A	   sta&s&cal	   significant	   associa&on	   between	   the	  
SpA	   group	   and	   IgG1	   &	   IgG3	   an&bodies	   against	  
human	  HSP60	  (Figure	  1D,	  p<0.001).	  
②  Cross-­‐reac&vity	   to	  bacterial	  HSP60	   could	  not	  be	  
supported.	  
③  IgG3	  an&bodies	  against	  human	  HSP60	  correlated	  
to	   disease	   ac&vity	   for	   HLA-­‐B27+	   pa&ents	  
(Spearman,	  r=0.48,	  p=0.001).	  
④  These	   results	   suggest	   that	   an&bodies	   against	  
human	  HSP60	   in	   connec&on	  with	  HLA-­‐B27	  may	  
be	  associated	  with	  SpA.	  	  	  
R	  e	  s	  u	  l	  t	  s	  
M	  e	  t	  h	  o	  d	  s	  
Spondy l o a r t h r i & s	   ( S pA )	   comp r i s e s	   a	  
heterogeneous	   group	   of	   inflammatory	   diseases,	  
with	   strong	   associa&on	   to	   human	   leukocyte	  
an&gen	  (HLA)-­‐B27.	  SpA	  is	  suggested	  triggered	  by	  
bacterial	   infec&on,	   and	   bacterial	   heat	   shock	  
protein	  (HSP)	  seems	  to	  be	  a	  strong	  T	  cell	  an&gen.	  
Since	   bacterial	   and	   human	   HSP60,	   also	   named	  
HSPD1,	   are	   highly	   homologous,	   cross-­‐reac&vity	  
has	   been	   suggested	   in	   disease	   ini&a&on.	   In	   this	  
study,	   levels	   of	   an&bodies	   against	   bacterial	   and	  
human	  HSP60	  were	  analysed	  in	  SpA	  pa&ents	  and	  
healthy	   controls,	   and	   the	   associa&on	   between	  
such	   an&bodies	   and	   disease	   severity	   in	   rela&on	  
to	  HLA-­‐B27	  was	  evaluated.	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Serum	   samples	   from	   82	   pa&ents	   and	   50	  
controls	   were	   analysed	   by	   Enzyme-­‐linked	  
immunoso rben t	   a s s ay	   ( E L I SA )	   fo r	  
immunoglobulin	  (Ig)G1,	   IgG2,	   IgG3	  and	  IgG4	  
an&bodies	  against	  human	  HSP60	  and	  HSP60	  
from	   Chlamydia	   trachoma.s,	   Salmonella	   e.	  
Enteri&dis	  and	  Campylobacter	  jejuni.	  Disease	  
severity	  was	  assessed	  by	  the	  clinical	  scorings	  
Bath	   Ankylosing	   Spondyli&s	   Disease	   Ac&vity	  
Index	   (BASDAI),	   Bath	   Ankylosing	   Spondyli&s	  
Func&onal	  Index	  (BASFI)	  and	  Bath	  Ankylosing	  
Spondyli&s	  Metrology	  Index	  (BASMI).	  	  
Pa2ents	  
Serum	   samples	   was	   collected	   from	   the	  
outpa&ent	   clinic	   at	   Aarhus	   University	   Hospital	  
afer	   informed	   wri\en	   consent	   was	   given,	  
according	  to	  the	  Danish	  Data	  Protec&on	  Agency,	  
the	   Local	   Ethics	   Commi\ee	   (project	   number	  









































































































































   A     C. trachomatis HSP60                   B                 C. jejuni HSP60 















































Figure	  3.	  An2body	  levels	  in	  the	  SpA	  &	  Control	  group	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Table	  1.	  Comparison	  of	  IgG1	  &	  IgG3	  an2bodies	  against	  human	  &	  bacterial	  HSP60	  
Median (IQR) 
IgG1 IgG3 
Statistical result of the 
Mann Whitney U test 
(p-value) 
Human HSP60 2.91 (1.71;6.53) 3.38 (1.31;21.42) P=0.53 
C. trachomatis HSP60 5.50 (3.07;10.81) 1.52 (1.07;3.08) p0.0001 
C. jejuni HSP60 2.14 (1.64;3.22) 1.64 (1.41;2.08) P=0.0001 
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** p<0.001; * p<0.01























Figure	  1.	  SDS	  PAGE	  
Size	  and	  purity	  of	  each	  recombinant	  protein	  were	  evaluated	  by	  10%	  SDS-­‐PAGE	  gel.	  	  
The	   different	   HSP60	   proteins	   for	   ELISA	   were	   purified	   using	   a	   Ni+	   column	   and	  
imidazole	   as	   a	   compe&ng	   reagent.	   Vector	   transforma&on	  was	   confirmed	  by	   IPGT	  
induc&on.	  Lane	  A:	  Molecular	  weight	  marker.	  Lane	  B,	  E,	  H	  &	  K:	  purified	  HSP60.	  Lane	  
C+D,	  F+G,	   I+J	  &	  L+M:	  Total	  protein	  content	   from	  E.	  coli	   strain	  BL21	  (DE3)	  with	  (+)	  
and	  without	  (-­‐)	  IPGT	  induc&on.	  
A	  standard	  curve	  made	  with	  Magellan	  data	  sofware	  used	  to	  quan&fy	  the	  A450nm	  
values	  from	  ELISA.	  An	  ELISA	  plate	  was	  coated	  with	  a	  known	  serial	  dilu&on	  (0.0625	  -­‐	  
4	  µg/mL)	  of	  na&ve	  IgG1	  subclass	  from	  human	  myeloma	  plasma	  before	  incuba&ng	  
wells	  with	  HRP-­‐conjugated	  secondary	  an&body.	  Correla&on	  between	  A450nm	  values	  
and	  concentra&on	  was	  fi\ed	  by	  the	  regression	  output	  (r	  =	  0.99507).	  
Table	  2.	  Spearman	  Rank	  Correla2ons	  coefficient	  (r)	  for	  the	  correa2on	  between	  an2-­‐human	  	  
HSP60	  IgG1	  &	  IgG3	  and	  BASDAI,	  BASFI	  &	  BASMI	  
